Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012-2018).
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers
/ blood
Cardiovascular Diseases
/ diagnosis
China
/ epidemiology
Cross-Sectional Studies
Drug Prescriptions
Drug Utilization
/ trends
Dyslipidemias
/ blood
Female
Hospital Information Systems
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ administration & dosage
Lipids
/ blood
Male
Middle Aged
Pharmacy Service, Hospital
Practice Patterns, Physicians'
/ trends
Primary Prevention
/ trends
Secondary Prevention
/ trends
Time Factors
Treatment Outcome
Young Adult
Cardiovascular disease
Initiation
Prevalence
Preventative intervention
Statins
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
25 04 2020
25 04 2020
Historique:
received:
20
01
2020
accepted:
12
04
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Statin remains a mainstay in the prevention and treatment of cardiovascular diseases. Statin utilization has evolved over time in many countries, but data on this topic from China are quite limited. This study aimed to investigate the changing trends of statins prescription, as well as detail the statin utilization through a successive longitudinal study. The prescription database was established based on electronic health records retrieved from the hospital information system of Jinshan Hospital, Fudan University from January 2012 to December 2018 in Shanghai, China. The prescription rates and proportions of different statin types and doses among all patients were examined. Sub-analyses were performed when stratifying the patients by age, gender, dose intensity, and preventative intervention. During the study period, a total of 51,083 patients, who were prescribed for statins, were included in this study (mean [SD] age, 59.78 [±13.16] years; 53.60% male, n = 27, 378). The overall statins prescription rate in which patients increased from 2012 (1.24, 95% CI: 1.21-1.27%) to 2018 (3.16, 95% CI: 3.11-3.20%), P < 0.001. Over 90% of patients were given a moderate dose of statins. Patients with a history of coronary and cerebrovascular events (over 32%) were more likely to be prescribed with statins for preventative intervention. Furthermore, our study has witnessed a significant rise in statin therapy in primary and secondary prevention. In conclusion, statins were frequently prescribed and steadily increased over time in our study period. There were also changes in statin drug choices and dosages. A coordinated effort among the patient, clinical pharmacist, stakeholders and health system is still needed to improve statin utilization in clinical practice in the future.
Sections du résumé
BACKGROUND
Statin remains a mainstay in the prevention and treatment of cardiovascular diseases. Statin utilization has evolved over time in many countries, but data on this topic from China are quite limited. This study aimed to investigate the changing trends of statins prescription, as well as detail the statin utilization through a successive longitudinal study.
METHODS
The prescription database was established based on electronic health records retrieved from the hospital information system of Jinshan Hospital, Fudan University from January 2012 to December 2018 in Shanghai, China. The prescription rates and proportions of different statin types and doses among all patients were examined. Sub-analyses were performed when stratifying the patients by age, gender, dose intensity, and preventative intervention.
RESULTS
During the study period, a total of 51,083 patients, who were prescribed for statins, were included in this study (mean [SD] age, 59.78 [±13.16] years; 53.60% male, n = 27, 378). The overall statins prescription rate in which patients increased from 2012 (1.24, 95% CI: 1.21-1.27%) to 2018 (3.16, 95% CI: 3.11-3.20%), P < 0.001. Over 90% of patients were given a moderate dose of statins. Patients with a history of coronary and cerebrovascular events (over 32%) were more likely to be prescribed with statins for preventative intervention. Furthermore, our study has witnessed a significant rise in statin therapy in primary and secondary prevention.
CONCLUSIONS
In conclusion, statins were frequently prescribed and steadily increased over time in our study period. There were also changes in statin drug choices and dosages. A coordinated effort among the patient, clinical pharmacist, stakeholders and health system is still needed to improve statin utilization in clinical practice in the future.
Identifiants
pubmed: 32334525
doi: 10.1186/s12872-020-01482-5
pii: 10.1186/s12872-020-01482-5
pmc: PMC7183656
doi:
Substances chimiques
Biomarkers
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
201Subventions
Organisme : Health Commission of Jinshan district, Shanghai
ID : JSKJ-KTMS-2019-17
Pays : International
Organisme : Qinglan Project of Jiangsu Province of China (CN)
ID : 2018-JSYYQH-05
Pays : International
Références
J Med Assoc Thai. 2015 Feb;98(2):129-36
pubmed: 25842792
Int J Environ Res Public Health. 2017 Nov 15;14(11):
pubmed: 29140293
Am J Med. 2015 Aug;128(8):914.e5-914.e10
pubmed: 25837518
BMC Health Serv Res. 2014 Jan 06;14:6
pubmed: 24393340
BMJ. 2006 Jun 10;332(7554):1344-5
pubmed: 16763226
Can Fam Physician. 2017 Nov;63(11):e495-e503
pubmed: 29138175
Eur J Prev Cardiol. 2020 May;27(8):870-881
pubmed: 32013600
BMJ Open. 2017 May 17;7(5):e014150
pubmed: 28515189
J Clin Lipidol. 2013 Jan-Feb;7(1):43-7
pubmed: 23351582
Clin Epidemiol. 2016 May 27;8:123-32
pubmed: 27313477
Am J Med. 2011 Sep;124(9):876-80.e2
pubmed: 21854896
J Am Coll Cardiol. 2015 Jul 14;66(2):184-92
pubmed: 26160634
J Geriatr Cardiol. 2018 Jan;15(1):1-29
pubmed: 29434622
Ann N Y Acad Sci. 2013 Jul;1290:37-51
pubmed: 23855464
Clin Ther. 2010 Mar;32(3):575-87
pubmed: 20399994
Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):475-84
pubmed: 19817531
Am Heart J. 2016 Nov;181:130-136
pubmed: 27823684
Intern Emerg Med. 2017 Dec;12(8):1121-1129
pubmed: 28597359
Ann Pharmacother. 2016 Jan;50(1):17-21
pubmed: 26416950
JAMA. 2015 Nov 3;314(17):1818-31
pubmed: 26529160
Atherosclerosis. 2019 Jan;280:174-182
pubmed: 30529830
J Saudi Heart Assoc. 2015 Jul;27(3):179-91
pubmed: 26136632
Chronic Dis Transl Med. 2016 Jun 07;2(1):7-9
pubmed: 29063018
BMC Fam Pract. 2009 Apr 21;10:24
pubmed: 19383116
J Clin Lipidol. 2016 Nov - Dec;10(6):1406-1413
pubmed: 27919358
BMC Clin Pharmacol. 2007 Dec 05;7:14
pubmed: 18053228
J Am Coll Cardiol. 2015 Jan 27;65(3):270-7
pubmed: 25614424
J Am Heart Assoc. 2017 May 4;6(5):
pubmed: 28473405
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Clin Cardiol. 2009 Jun;32(6):308-14
pubmed: 19569062
Br J Clin Pharmacol. 2007 Oct;64(4):476-81
pubmed: 17441934
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
Cardiovasc Drugs Ther. 2018 Aug;32(4):397-404
pubmed: 30062465
Pharmacotherapy. 2012 Jul;32(7):631-41
pubmed: 22760692
Med Care. 2010 Sep;48(9):761-6
pubmed: 20706164
Am Health Drug Benefits. 2016 Nov;9(8):434-444
pubmed: 28465771
BMC Cardiovasc Disord. 2018 Nov 6;18(1):209
pubmed: 30400778
JAMA Cardiol. 2017 Jan 1;2(1):56-65
pubmed: 27842171
J Clin Lipidol. 2018 Jul - Aug;12(4):1008-1018.e1
pubmed: 29703626